|
|
||||||||





* Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia;
Department of Dermatology, National Hospital Organization, Osaka Minami Medical Centre, Kawachinagano, Japan;
Department of Dermatology, Osaka University Medical School, Suita, Japan;
Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; and
¶ Institute for Virology and Immunobiology, University of Wuerzburg, D-97078 Wuerzburg, Germany
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
C57BL/6 (B6), B6.SJL-PtprcaPep3b/BoyJ (B6.Ly5.1), B6.C-H-2bm-1 (bm1) (15), RIP.OVAhigh (16), K5m.OVA (17), K5.mOVA x bm1, K5.mOVA x B6.Ly5.1, OT-I x B6.Ly5.1, and gBT-I x B6.Ly5.1 mice were bred and maintained at the Department of Microbiology and Immunology, University of Melbourne or at the Walter and Eliza Hall Institute of Medical Research.
Preparation and adoptive transfer of CFSE-labeled OT-I or gBT-I T cells
OT-I or gBT-I T cells were prepared by generating a single-cell suspension of LNs (axillary, brachial, inguinal, cervical, and mesenteric) and/or spleen cells from either OT-I or gBT-I transgenic mice. In some experiments, OT-I or gBT-I T cells were purified. Single-cell suspensions were incubated for 30 min with predetermined optimal concentrations of the following purified mAbs: anti-Mac-1
(M1/70), anti-F4/80 (F4/80), anti-erythrocyte (TER-119), anti-GR-1 (RB68C5), anti-I-A/I-E (M5114), and anti-CD4 (GK1.5). The Ab-coated cells were then removed by incubation with sheep anti-rat IgG-coupled magnetic beads (Dynabeads: Dynal Biotech) or goat anti-rat IgG-coupled magnetic beads (Qiagen). Purity was determined by propidium iodide (PI) exclusion of cells stained with anti-CD8 and V
2.
For CFSE labeling, OT-I or gBT-I T cells were resuspended in PBS containing 0.1% BSA (Sigma-Aldrich) and labeled with 2.5 µM CFSE (Molecular Probes) for 10 min at 37°C. Cells were then washed twice in HEPES MEM. A total of 106 CFSE-labeled OT-I T cells (Ly5.1+, CD8+, and V
2+) were adoptively transferred by i.v. injection into recipient mice. After 42 h, pooled brachial and inguinal LNs from individual mice were analyzed by flow cytometry for proliferation of Ly5.1+CD8+CFSE+PI– cells. For in vivo experiments aimed at analyzing proliferation, unenriched CFSE-labeled OT-I T cells from the LNs were used. For experiments involving in vivo deletion and naive CD8+ T cell stimulation by DCs in vitro, purified OT-I or gBT-I T cells were used.
Viral infections
K5.mOVA mice, 6–12 wk old, were inoculated with 1 x 106 PFUs of HSV (KOS strain of HSV-1) on both sides via the flank scarification model as previously described (18). K5.mOVA or C57BL/6 mice, 6–12 wk old, were inoculated with 500 PFU of a recombinant influenza virus carrying the MHC class I-restricted OVA injected s.c. into each hind footpad.
Flow cytometric analysis of OT-I T cell expansion
K5.mOVA or C57BL/6 mice that received 1 x 105 OT-I x B6.Ly5.1 LN cells 4 wk earlier were inoculated with a recombinant influenza virus carrying the MHC class I-restricted OVA via foothock infection. Seven days after infection, mice were sacrificed and their spleens were removed. Single-cell suspensions were stained with anti-Ly5.1-FITC (A20), anti-V
2-PE (B20.1), and anti-CD8
-allophycocyanin (53-6.7). Stained cell solutions were analyzed by flow cytometry with PI used to exclude dead cells.
DCs isolation from LNs
The s.c. draining LNs (brachial, inguinal, and cervical) were removed from mice. The LN were cut into small fragments and digested for 20 min at room temperature in a collagenase/DNase solution (1 mg/ml collagenase type II; Worthington Biochemicals) and 0.1% grade II bovine pancreatic DNase I (Boehringer Mannheim) in mouse tonicity RPMI 1640 containing 10% FCS, 50 µM 2-ME, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (complete RPMI medium). To disrupt T cell-DC complexes, 0.1 M EDTA was added to the suspension and digested for a further 5 min at room temperature. All subsequent procedures were in balanced salt solution/EDTA/5% FCS. DCs were purified from the single-cell suspensions as described previously (7). In brief, the single-cell suspensions were incubated for 30 min with predetermined optimal concentrations of the following purified mAbs: anti-CD3
(KT3), anti-Thy-1 (T24/31.7), anti-CD19 (ID3), and anti-erythrocyte (TER-119). The Ab-coated cells were then removed by incubation with sheep anti-rat IgG-coupled magnetic beads (Dynabeads; Dynal Biotech). For purification of LN DCs into their different phenotypic populations, DCs were labeled with anti-CD11c-FITC (N418), anti-CD205-PE (NLDC-145), and anti-CD8
-allophycocyanin (53-6.7; BD Pharmingen) specific mAbs and sorted on a MoFlo flow cytometer (Cytomation).
DCs that expressed langerin were identified by incubating cells for 30 min in anti-CD16/32 (2.4G2) supernatant before staining with anti-mouse CD207 (langerin, 205C1; AbCys). Ab-bound cells were detected using anti-mouse IgMa-PE (AF6-78; BD Pharmingen). PI was used to exclude dead cells from the sorts.
Coculture of DC subpopulations with CFSE-labeled OT-I or gBT-I T cells
Two-fold serial dilutions starting at 2.5 x 104 of each DC population were cocultured in vitro with 5 x 104 CFSE-labeled OT-I or gBT-I T cells in 200 µl of complete RPMI medium in V-bottom tissue-culture plates (Costar). Proliferation was measured as a loss of CFSE staining of CD8+Ly5.1+PI– cells as determined by flow cytometric analysis (FACSCalibur; BD Biosciences) after 60 h of culture.
Analysis of T cell deletion
A total of 5 x 106 OT-I T cells (Ly5.1+, CD8+, V
2+) were adoptively transferred into recipient mice and, after 6 wk, the mice were analyzed. Cells were pooled from the axillary, brachial, inguinal, cervical, and mesenteric LNs and spleen of each recipient mouse. Cells were stained with anti-Ly5.1-FITC (A20) and anti-CD8
-allophycocyanin (53-6.7), together with either anti-V
2-PE (B20.1) or H-2Kb-OVA257–264-PE tetramer. Live lymphocytes were determined by forward and side scatter profiles together with PI exclusion. Analysis was performed on a FACSCalibur flow cytometer. A total of 2 x 105 live cells were collected for analysis. The number of OT-I cells per animal was enumerated using a known number of small nonfluorescent Sphero beads (BD Biosciences) added to a known volume of the cell sample. Therefore cells per milliliter = number cells collected x (number beads in sample/number beads collected)/sample volume (19).
Generation of bone marrow chimeras
Chimeric mice were generated by irradiation of recipient mice with two doses of 550 cGy, 3 h apart, and reconstituted with 5 x 106 T cell-depleted donor bone marrow cells. Donor bone marrow cells were depleted of T cells by labeling cell suspensions with the following mAbs: anti-CD4 (RL172), anti-CD8 (3.168), and anti-Thy-1 (J1J). The Ab-coated cells were removed by incubation with rabbit complement for 30 min at 37°C. The following day, residual radio-resistant T cells were depleted with 100 µl of T24 (anti-Thy-1) ascites i.p. The mice were allowed to reconstitute for 8–10 wk before use.
DCs isolation from skin biopsies
Dermal DCs and/or epidermal DCs were isolated from either whole skin or epidermal sheets, respectively, by culture in the presence of 6Ckine (R&D Systems) as described previously (7). Mice were clipped along the flank and depilated with Veet (Reckitt Benckiser). Full-thickness skin was harvested from the flank region. The s.c. tissue was removed using a scalpel blade and the skin was cut into small pieces. The skin was floated (dermal side down) on 1 ml of complete RPMI medium containing 0.1 µg of recombinant mouse 6Ckine to promote DC migration. After 24 h incubation at 37°C, the emigrant cells were collected and placed at 4°C. The skin was transferred into fresh medium containing 6Ckine and incubated for a further 24 h at 37°C. Cells that migrated into the culture medium over the first and second incubations were pooled before staining for FACS analysis.
For DCs derived from the epidermal sheet crawlouts, the skin pieces were floated dermal side down in complete RPMI medium containing 2.5 mg/ml dispase II (Roche) for 90 min at 37°C. Epidermal sheets were peeled from the dermis and treated the same as whole skin crawlouts. The phenotype of DCs isolated from skin was analyzed by staining isolated cells with various combinations of the following Abs: anti-CD45.2-FITC (104; BD Pharmingen), anti-CD205-PE (NLDC-45) or anti-I-Ab-PE (AF6-120.1; BD Pharmingen), and anti-CD11c-biotin (HL3; BD Pharmingen) or anti-H-2Kb-biotin (5F1), followed by an allophycocyanin-streptavidin (BD Pharmingen). Dead cells were excluded with PI. Analysis was performed on a FACSCalibur flow cytometer.
Direct isolation of epidermal DCs from skin biopsies
For direct isolation of epidermal DCs, skin was excised as described above. The small skin pieces were floated dermal side down in complete RPMI medium containing 2.5 mg/ml dispase II for 90 min at 37°C. The epidermal sheets were peeled from the dermis and homogenized using a scalpel blade. Samples were then digested in 3 ml of collagenase (3 mg/ml collagenase type III; Worthington Biochemicals) in mouse tonicity RPMI 1640 containing 2% FCS, 50 µM 2-ME, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin) per mouse for 30 min at 37°C. Samples were preincubated with anti-CD16/32 (2.4G2 supernatant) to block nonspecific Ab binding. All subsequent procedures were performed in balanced salt solution/EDTA/5% FCS. Samples were stained with anti-CD11c-biotin (HL3; BD Pharmingen) and anti-langerin (205C1; AbCys) followed by allophycocyanin-conjugated streptavidin (BD Pharmingen) and anti-mouse IgMa-PE (AF6-78; BD Pharmingen). Other mAbs used were anti-I-Ab-FITC (AF6-120.1; BD Pharmingen), anti-CD86-FITC (GL1), and anti-CD40-FITC (FGK45.5). PI was included to exclude dead cells. Analysis was performed on a FACSCalibur flow cytometer.
| Results |
|---|
|
|
|---|
Azukizawa et al. (17) generated a transgenic mouse expressing a membrane-bound form of OVA under the control of the keratin K5 promoter. In this mouse, Ag expression was confined to selected tissues including the skin epidermis and this resulted in preferential proliferation of CFSE-labeled OVA-specific OT-I T cells in skin draining LNs (Fig. 1A). We wanted to examine the DC subset presentation of Ag in these LNs. Given that transgene expression is confined to epidermis of the skin, we first assessed whether DCs originating from this location, the Langerhans cells, presented class I-restricted OVA peptide. To this end, CD11c+ cells from skin-draining LNs were separated on the basis of expression of a Langerhans cell-specific marker, CD207 (langerin (20)) and CD8 (Fig. 1B). The latter was included because CD8+ DCs can present Ag after cutaneous viral infection (6, 7, 9). The purified DC populations were used to stimulate CFSE-labeled OVA-specific T cells from the OT-I transgenic mouse (21) in an in vitro proliferation assay. Fig. 1C shows that while purified Langerhans cell progeny can effectively present the class I-restricted Ag, there is little activity within the CD8+ DC subset. Interestingly, some presentation is also seen in the CD207–CD8– population, which consists of a number of distinct DC subsets including the dermal and myeloid, nonmigratory resident DCs.
|
|
Langerhans cell precursors are known to be radiation resistant (7, 22), although at the start of this study it had been unclear to what extent the dermal DCs are replaced in these bone marrow chimeras. We resolved this by comparing migrating DCs in explant cultures of epidermal sheets (which should contain exclusively Langerhans cells) and whole skin (which also have the dermal-derived DC component) from bone marrow chimeric mice differing in expression of CD45 allotypes (Fig. 3). Again, Langerhans cells can be distinguished from dermal DCs by their higher expression of CD205 (2, 3). Fig. 3 shows that the CD205high Langerhans cells migrating from the epidermal sheets were almost exclusively of host (CD45.2) origin (Fig. 3A), confirming their resistance to irradiation. In contrast, a large proportion of whole skin migrants were of donor (CD45.1) origin (Fig. 3B). The CD205int dermal DCs in these emigrating populations had undergone
90% replacement, while most of the CD205high cells were of host origin reflecting their Langerhans cell classification. These are slightly lower levels of dermal DC replacement than recently reported by Bogunovic et al. (23), who found around 25% of dermal DCs survive irradiation. All other non-skin-derived DCs in the draining LNs are of host origin (data not shown). Thus, irradiation chimeras contain a population of largely donor-derived skin and non-skin origin DCs compared with host-derived Langerhans cells.
|
K5mOVA chimeric animals. Put simply, these chimeras have most of their Langerhans cells and even a small proportion of dermal DCs still capable of presenting the skin-acquired Ag. However, these particular chimeras were originally described as lacking in vivo stimulatory capacity (17). It should be noted that the original data showed some stimulatory capacity remained in these animals and it was not appreciated that this residual activity could result from the surviving radio-resistant Langerhans cells. The level of residual presentation is shown here in Fig. 4. The bm1
K5mOVA animals are seen to support much weaker proliferation of the transferred CFSE-labeled OT-I cells (Fig. 4A) than the K5mOVA
K5mOVA chimeric animals (Fig. 4B). Although stimulation of transferred OT-I cells is reduced in the bm1
K5mOVA chimeras, it is clearly stronger than seen in negative controls such as the non-Ag-expressing K5mOVA
B6 or bm1
B6 animals (Fig. 4, C and D). In retrospect, attenuated but not absent stimulation of OT-I T cells is to be expected because the K5mOVA
K5mOVA animals have both dermal DCs and Langerhans cells capable of presenting the Kb-restricted OVA peptide, whereas presentation is predominantly confined to the Langerhans cell subset in bm1
K5mOVA chimeras. Overall, CD207+ Langerhans cells make up <20% of all skin-derived DCs in the LNs (where the latter is measured as the CD205+CD8–CD11c+ population) (Fig. 4E), explaining the weaker stimulation seen in these latter chimeric animals where Langerhans cells and relatively few radio-resistant dermal DCs are the only cells capable of Ag presentation. Finally, robust stimulation of OT-I T cells in K5mOVA. Langerin-DTR mice that have the diptheria toxin receptor driven by the langerin promoter, even after ablation of Langerhans cells by diptheria toxin treatment (data not shown), exclude Langerhans cells as sole contributors to skin-derived Ag presentation.
|
Skin-derived DCs, such as the Langerhans cells that have migrated to the LN, are considered the prototypic mature DC subset (25), especially in contrast to their direct immature predecessors in peripheral tissues (26). This difference in maturation status was confirmed by showing that skin-derived CD11c+CD207+ cells (Langerhans cells) in the LN expressed high levels of maturation markers MHC class II and CD86 (Fig. 5), whereas their tissue-derived counterparts, the CD11c+CD207+ cells in the epidermis, exhibited low-level expression of these maturation markers. It should be noted that while low, this staining was nonetheless clearly above background. Finally, CD205intCD8– dermal DCs in skin-draining LNs also show a mature status when assessed using these costimulatory markers (data not shown).
|
K5.mOVA.bm1 mice (Fig. 6B), consistent with the replacement of most of the host Kbm1-bearing dermal DCs with those of B6 origin, capable of presenting the tolerogenic peptide. Most importantly, deletion is evident in the bm1
K5.mOVA chimeric animals (Fig. 6B) where the epidermal Langerhans cells are clearly of host origin (Fig. 6C) and therefore capable of presenting the class I-restricted OVA peptide. Finally, transferred OT-I T cells are functionally tolerant in the K5.mOVA mice because their expansion is severely impaired on subsequent challenge with a recombinant influenza virus carrying the OVA peptide determinant (Fig. 6D). Combined with the data above on migratory DC maturation once they reach the LNs, these results suggest that the mature descendants of DCs that originate in the skin can drive deletional tolerance of self-reactive T cells.
|
Skin infection with cytopathic viruses such as HSV and vaccinia virus is associated with CD8+ DC presentation of class I-restricted Ag (6, 7, 8, 9). We were interested whether such infection would modify DC subset presentation of skin-derived self-Ag. To this end, we infected the K5.mOVA mice with HSV and examined DC subset presentation of both the self-Ag to the OT-I T cells and the foreign HSV gB peptide to the corresponding virus-specific T cells from the gBT-I transgenic mouse (29). Fig. 7 shows no alteration in the dominance of skin-derived DC presentation in the case of the OVA peptide. Conversely, all presentation of the HSV Ag was confined to the CD8+ DC subset, as found in previous studies. Thus, infection does not alter the pattern of self-Ag presentation, which is intrinsically distinct from the presentation of the virus-derived peptide.
|
| Discussion |
|---|
|
|
|---|
Interestingly, class I-restricted presentation of skin-expressed Ag clearly does not occur in the case of skin infection with viruses such as HSV, where an exclusion of skin-derived DC presentation is observed. This could indicate that this type of infectious agent inactivates the cross-presentation pathway, for example, by maturing these cells (35), or that it inactivates the DCs themselves, for example by directly killing infected cells (36, 37). Both these scenarios are still compatible with steady state presentation of self-Ag in the face of infection, which presumably reflects Ag acquisition and migration before infection.
We show that skin-derived DC presentation of self-Ag leads to deletional tolerance. Propositions for a skin-derived DC role in T cell down-modulation are not without precedent. Ablation of Langerhans cells has been shown to lead to exacerbation of contact sensitization in some (12) but not other (32) (33) transgenic mouse systems, and individuals with psoriasis have been found to have defects in Langerhans cell migration (11), suggesting that these cells may under some circumstances play a regulatory role dampening immune responses. However, skin-derived DCs have also been linked to certain types of antiviral immunity, especially those associated with noncytopathic infections (8). Thus, a purely tolerogenic role for this population may prove unlikely. Regardless, skin DC-mediated tolerance in the steady state is surprising given that these cells appear mature within the draining LNs as defined by markers such as MHC class II and accessory molecule expression. This is most striking in the case of Langerhans cells. These are the prototypic migrating DCs and it has been assumed that the concomitant phenotypic maturation acts as a key driver of T cell immunity. Although it is tempting to speculate that the phenotypic changes such as the up-regulation of costimulatory molecules are intimately tied to continuous exposure to environmental agents within the skin, it may simply form part of the constitutive migrational pathway and, as such, be independent of direct DC activation (38). As a consequence, migration may be associated with more indirect maturation that would, in turn, not convert DCs to their immunogenic form. It has been shown that while DC activation resulting from engagement of TLRs directly translates to effective immunity, indirect cytokine-mediated maturation is deficient in this respect (39). Thus, Langerhans cell migration in the absence of some form of additional immunogenic stimulation appears to result in an apparently mature DC population, which is nonetheless capable of driving deletional T cell tolerance.
Given the tolerance observed here, our results appear to contradict earlier work by Mayerova et al. (14) and Shibaki et al. (40) who showed that presentation of self-Ag by skin-derived DCs led to autoimmune tissue destruction. We were unable to explain these differences, although it should be noted that while here we show the elimination of the transferred OT-I T cells, these T cells also exhibited autoaggressive behavior at the microscopic level (17). Indeed, deletion and autoimmunity are not necessarily mutually exclusive. It is known that presentation of self-Ag by tolerogenic APCs can lead to varying levels of T cell activation before their functional elimination, ranging from fairly muted responses (41) to full-blown induction of effector function (42). What controls this apparent continuum that ranges from the largely proliferative T cell response, as seen here, to an overtly autoaggressive response, as seen in Kurts et al. (27), remains undefined.
In summary, we have focused on the difference in the presentation mediators that operate during virus infection of the skin and the establishment of tolerance to skin-derived Ag. In our studies, tolerance is mediated by the migratory DCs, including the Langerhans cells derived from the epidermal layer harboring Ag expression. Moreover, this tolerance is achieved despite these cells appearing phenotypically mature once they reach the skin-draining LNs.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by grants from the Australian National Heath and Medical Research Council, The Wellcome Trust, and the Howard Hughes Medical Institute. ![]()
2 Address correspondence and reprint requests to Dr. William R. Heath, Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, Australia; E-mail address: heath{at}wehi.edu.au or Dr. Francis R. Carbone, Department of Microbiology and Immunology, University of Melbourne, Parkville 3010, Australia; E-mail address: fcarbone{at}unimelb.edu.au ![]()
3 Abbreviations used in this paper: DC, dendritic cell; LN, lymph node; PI, propidium iodide. ![]()
Received for publication February 9, 2007. Accepted for publication July 17, 2007.
| References |
|---|
|
|
|---|
+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J. Immunol. 170: 4437-4440.
+ dendritic cells but not by Langerhans cells. Science 301: 1925-1928.
+ dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172: 1996-2000. This article has been cited by other articles:
![]() |
M. Holcmann, P. Stoitzner, B. Drobits, P. Luehrs, G. Stingl, N. Romani, D. Maurer, and M. Sibilia Skin Inflammation Is Not Sufficient to Break Tolerance Induced against a Novel Antigen J. Immunol., July 15, 2009; 183(2): 1133 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Bianchi, L. B. Pincus, M.-A. Wurbel, B. E. Rich, T. S. Kupper, R. C. Fuhlbrigge, and M. Boes Maintenance of Peripheral Tolerance through Controlled Tissue Homing of Antigen-Specific T Cells in K14-mOVA Mice J. Immunol., April 15, 2009; 182(8): 4665 - 4674. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Lee, M. Zamora, M. M. Linehan, N. Iijima, D. Gonzalez, A. Haberman, and A. Iwasaki Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection J. Exp. Med., February 16, 2009; 206(2): 359 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Angel, C.-J. J. Chen, O. C. Horlacher, S. Winkler, T. John, J. Browning, D. MacGregor, J. Cebon, and P. R. Dunbar Distinctive localization of antigen-presenting cells in human lymph nodes Blood, February 5, 2009; 113(6): 1257 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. U. Eriksson and R. R. Singh Cutting Edge: Migration of Langerhans Dendritic Cells Is Impaired in Autoimmune Dermatitis J. Immunol., December 1, 2008; 181(11): 7468 - 7472. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hildner, B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, et al. Batf3 Deficiency Reveals a Critical Role for CD8{alpha}+ Dendritic Cells in Cytotoxic T Cell Immunity Science, November 14, 2008; 322(5904): 1097 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Waithman, T. Gebhardt, G. M. Davey, W. R. Heath, and F. R. Carbone Cutting Edge: Enhanced IL-2 Signaling Can Convert Self-Specific T Cell Response from Tolerance to Autoimmunity J. Immunol., May 1, 2008; 180(9): 5789 - 5793. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |